Vutrisiran CAS 1867157-35-4

Identification

CAS Number

1867157-35-4

Name

Vutrisiran

Properties

Safety Data

Symbol

Signal Word

Warning

WGK Germany

3

MSDS Download

Specifications and Other Information of Our

Identification Methods

HNMR, HPLC

Purity

Known Application

Vutrisiran is an investigational subcutaneously administered RNAi therapeutic indicated for the treatment of transthyretin-mediated (ATTR) amyloidosis, including hATTR and wild-type ATTR (wtATTR) amyloidosis. It blocks the production of wild-type and variant transthyretin (TTR) by targeting and silencing specific mRNAs.

General View of Documents

This product is developed by our R&D company Watson Bio Limited (https://www.watson-bio.com/).

This product is sold exclusively through our sales company Watson International Limited, and please click the link below for details (https://www.watson-int.com/).